What is Altimmune, Inc.'s current stock price?

Altimmune, Inc. (0A4C.L) currently trades at USD 6.11. Track real-time price changes and historical performance on AllInvestView.

What sector is Altimmune, Inc. in?

Altimmune, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Altimmune, Inc. 0A4C.L · Stock Open Altimmune, Inc. in new tab

6.11 USD

Add to portfolio

EPS

-2.39

P/B

2.85

ROE

-63.29

Beta

0.11

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Altimmune, Inc. (0A4C.L)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Altimmune, Inc. Analysis (0A4C.L)

United States Health Care Official Website Stock

Is Altimmune, Inc. a good investment? Altimmune, Inc. (0A4C.L) is currently trading at 6.11 USD.

Investor FAQ

Does Altimmune, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Altimmune, Inc.?

Altimmune, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Exchange Ticker

MEX (Mexico) ALT1.MX

FRA (Germany) 3G0.F

NMS (United States) ALT

LSE (United Kingdom) 0A4C.L

Trades

No dividend information available for this instrument.

Altimmune, Inc. 0A4C.L · Stock Open Altimmune, Inc. in new tab

Key Metrics

Growth

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Altimmune, Inc. Analysis (0A4C.L)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Altimmune, Inc. 0A4C.L · Stock Open Altimmune, Inc. in new tab

Key Metrics

Growth

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Altimmune, Inc. Analysis (0A4C.L)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications